Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
24 May 2024 - 10:00PM
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical
company focused on developing modality-agnostic targeted therapies,
today announced that Nadim Ahmed, Chief Executive Officer and
Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in
a fireside chat at the TD Cowen 5th Annual Oncology Innovation
Summit: Insights for ASCO & EHA, being held virtually on May 28
and 29, 2024.
The fireside chat is scheduled for Wednesday, May 29, 2024 at
11:30am Eastern Time. A webcast will be available under the Events
and Presentations section of the Company’s investor relations
website at
https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a
biopharmaceutical company dedicated to creating new standards of
care for patients. We have strategically built a diversified
portfolio of clinical-stage assets that inhibit key drivers of
disease or harness the immune system to eliminate diseased cells in
both oncology and autoimmune diseases. Our portfolio encompasses a
wide range of modalities, each with the potential to be best and/or
first in class. Anchored in a deep understanding of oncology,
immunology, and translational medicine, we create differentiated
ideas, identify the most appropriate targets, and select the
optimal modality to develop transformative therapeutics across a
wide variety of cancer and autoimmune indications. We push
conventional boundaries from candidate selection to differentiated
therapeutic, applying rigorous go/no go criteria at each stage of
development to fast-track only the most promising molecules to the
clinic and, ultimately, commercialization. With deep scientific
expertise, our teams exercise creativity and urgency to deliver on
our promise to bring new therapeutic solutions to patients. Learn
more about our Company at https://cullinantherapeutics.com/, and
follow us on LinkedIn and X.
Contacts: Investor Relations Chad
Messer +1 203.464.8900 cmesser@cullinantx.com
Media Rose Weldon +1
215.801.7644 rweldon@cullinantx.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jan 2024 to Jan 2025